SpineX Scone
[Image from SpineX]

SpineX announced today that it enrolled the first patient in its pivotal trial evaluating the Scone neuromodulation device.

Los Angeles-based SpineX will evaluate the safety and effectiveness of the non-invasive spinal neuromodulation technology for the treatment of neurogenic bladder.

The first patient was enrolled at the Rancho Research Institute of the Rancho Los Amigos National Neurorehabilitation Center in Downey, California, according to a news release.

SpineX designed Scone therapy to treat symptoms such as the lost sensation of bladder fullness, low bladder capacity, frequent urination cycles during both day and night and living with constant fear of uncontrolled urine leakage.

Dr. Evgeniy Kreydin, the company’s co-founder and assistant professor at the University of Southern California, Los Angeles, said in the release that while the inability to walk is the most obvious functional loss for a person in a wheelchair, “the impact on quality of life due to neurogenic bladder is unparalleled.”

“The initiation of the Scone trial is an important milestone in bringing the world’s first non-invasive treatment modality for neurogenic bladder to market,” SpineX CEO Parag Gad said. “We are committed to transforming bladder management into a catheter free and leak free world.”